HUTCHMED (LON:HCM) Reaches New 12-Month Low – Time to Sell?

Posted by on Jun 3rd, 2026

HUTCHMED (China) Limited (LON:HCM – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 170 and last traded at GBX 175, with a volume of 14706 shares traded. The stock had previously closed at GBX 174.

HUTCHMED Stock Up 0.6%

The firm’s 50-day simple moving average is GBX 201.10 and its 200-day simple moving average is GBX 209.85. The company has a market capitalization of £1.50 billion, a price-to-earnings ratio of 3.30 and a beta of 0.45. The company has a debt-to-equity ratio of 7.91, a quick ratio of 2.97 and a current ratio of 4.96.

HUTCHMED Company Profile

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

Featured Articles

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.